3 of the best ASX 200 stocks to buy in FY25

Big returns and buy ratings. That's what Bell Potter is saying about these shares.

| More on:
Four people gather around laptop and cheer

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new financial year is on the horizon, so what better time to make some new additions to your investment portfolio.

But which ASX 200 stocks could be buys?

Let's take a look at three best buys for FY 2025 according to analysts at Bell Potter. They are as follows:

Bega Cheese Ltd (ASX: BGA)

Bell Potter sees a lot of value in this diversified food company's shares. Particularly given that its outlook is becoming more positive and its shares are trading on historically low forward earnings multiples. It explains:

Our Buy rating remains on BGA is based on: (1) a historically low forward multiple; (2) consolidating milk processing infrastructure; and (3) the material valuation upside should BGA execute on its 5 year targets. In addition, we note that the key drivers of FY25e appear to have improved in recent months, with: (1) Australian milk production continuing to demonstrate YOY growth through 4Q24; (2) YOY gains in SMP pricing in FY25e futures markets; and (3) a material YOY downdraft in farmgate milk prices in FY25e based on minimum opens by major processors.

Bell Potter has a buy rating and $5.35 price target on its shares. This implies potential upside of 26% for investors over the next 12 months.

Neuren Pharmaceuticals Ltd (ASX: NEU)

Another ASX 200 stock that Bell Potter is bullish on for FY 2025 is biotechnology company Neuren Pharmaceuticals.

The broker believes it could be a great long term pick for patient investors. It explains:

In the last six months, NNZ-2591 reported highly encouraging Phase 2 data in two rare diseases. NEU will once again have first-to-market opportunities in these two rare diseases, assuming future Phase 3 trials are successful. While short-term news will continue to be impacted by Acadia's commercialisation of NEU's first drug, called Daybue, we maintain our BUY recommendation for investors who have a longer 2 to 3-year investment horizon.

Bell Potter has a buy rating and $28.00 price target on its shares. This suggests that potential upside of 32% is possible from current levels.

Boss Energy Ltd (ASX: BOE)

If you're not averse to investing in the mining sector, then this uranium miner could be an ASX 200 stock to buy according to Bell Potter.

The broker sees "significant value" in its shares right now. Especially given its geographically diversified multi-asset portfolio and the uranium bull market. It said:

BOE's Honeymoon project recommenced production in April-24, with first sales expected in July-24. The business over the last six months has changed somewhat, with the acquisition of a 30% interest in the Alta Mesa project with JV partner enCore energy in South Texas. We continue to see significant value in BOE, with optionality around expansion at Honeymoon via low-risk and cost regional resources at Jasons and Goulds Dam. With the inclusion of Alta Mesa, BOE boasts a geographically diversified multi-asset portfolio with several growth levers yet to be pulled, heading into a uranium bull market.

Bell Potter has a buy rating and $6.35 price target. This implies potential upside of 54% for investors.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A group of young ASX investors sitting around a laptop with an older lady standing behind them explaining how investing works.
Broker Notes

10 ASX shares to buy in FY25

Analysts say investors should buy these stocks in the new financial year.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

These ASX shares can rise 25% to 40%

Analysts think these shares could deliver big returns for investors.

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Broker Notes

Bell Potter names 3 of the best ASX 200 stocks to buy in July

These shares have been given a big thumbs up by the broker this month.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Financial Shares

Up 15% in a month: Are Magellan shares still cheap enough to buy?

The decision is split among brokers – still.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Morgans names the best ASX stocks to buy in July

What is the broker saying about these stocks this month?

Read more »